The outlook revision is based on a number of factors, including Moody’s Investors Service’s expectation that AHS will continue to maintain strong operating performance and will improve balance sheet metrics.
Moody’s also assigned an “A1” rating to AHS’ proposed series 2016 revenue refunding bonds, affecting $225.7 million. The rating affirmation reflects AHS’ favorable market position, strong revenue growth and maintenance of balance sheet metrics.
More articles on healthcare finance:
Accipiter Capital ups stake in CHS
Zika babies cost up to $10M in healthcare spending
4 hospital CFOs in the headlines
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
